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Background: The therapeutic potential of mesenchymal stem cells (MSCs) is hindered by their low survival rate after transplantation in post-
infarct heart. Statins, a convincing candidate to reduce MSCs apoptosis, has been proved to have connections with autophagy. Autophagy is a 
complex “self-eating” process and could be utilized for cell survival under stresses, which is positively regulated by AMP-activated protein kinase 
(AMPK)/ mammalian target of rapamycin (mTOR) pathway.
Methods: Bone morrow-derived MSCs from rats were exposed to hypoxia/ serum deprivation (H/SD) for 6 hours with different concentration of 
atrovastatin (ATV) (0.001μM, 0.01μM, 0.1μM, 1μM and 10μM). The levels of autophagy and apoptosis were detected by flow cytometry, western 
blotting and transmission electron microscopy.
Results: ATV-treated MSCs showed enhanced autophagy compared with untreated ones under H/SF, especially in 1μM concentration, as identified 
by increased acidic vesicular organelles (AVO)-positive cells (6.36±0.83% vs. 4.67±0.63%, p=0.007), the type II: type I ratio of light chain 3 protein 
(LC3-II/LC3-I ratio) (1.39±0.11 vs.0.89±0.15, p<0.001) and autophagosomes formation. Autophagy inhibitor 3-mechyladenine (3-MA) attenuated 
ATV- induced autophagy and increased apoptosis in ATV-treated MSCs. While rapamycin, a well-known inducer of autophagy, did not further 
enhanced autophagy compared with ATV alone. The phosphorylation of AMPK was upregulated (1.57±0.13 vs.0.86±0.11, p<0.001) whereas the 
phosphorylation of mTOR was downregulated (0.60±0.29 vs.1.29±0.19, p=0.002) in 1μM ATV-treated MSCs compared with untreated ones, which 
were both counteracted by AMPK inhibitor compound C. Furthermore, compound C also reduced the autophagy observed in 1μM ATV-treated MSCs 
under H/SF (AVO-positive cells: 3.53±0.56 vs.6.35±0.65, p<0.001; LC3-II/LC3-I ratio: 0.61±0.23 vs. 1.33±0.17, p<0.001).
Conclusions: ATV effectively activates autophagy via AMPK/mTOR pathway to reduce MSCs apoptosis during H/SF.
